51726-77-3

Usage

Uses

Used in Pharmaceutical Industry:
4-Hydroxy-7-Methylquinoline-3-carboxylic acid is used as an intermediate in the synthesis of various pharmaceuticals for its potential therapeutic applications. Its unique structure and functional properties make it a promising candidate for the development of anti-cancer, anti-infective, and anti-inflammatory drugs.
Used in Agrochemical Industry:
4-Hydroxy-7-Methylquinoline-3-carboxylic acid is used as an intermediate in the synthesis of agrochemicals, contributing to the development of effective and safe products for agricultural applications.
Used in Anti-cancer Applications:
4-Hydroxy-7-Methylquinoline-3-carboxylic acid is being studied for its potential use in anti-cancer drugs due to its unique structure and functional properties. It may exhibit inhibitory effects on tumor growth and progression, and could be combined with conventional chemotherapeutic drugs to enhance chemo-sensitivity and efficacy in resistant cases.
Used in Anti-infective Applications:
4-Hydroxy-7-Methylquinoline-3-carboxylic acid has shown antimicrobial activities, making it a valuable compound for the development of anti-infective drugs. Its potential use in this area could contribute to the treatment and prevention of various infectious diseases.
Used in Anti-inflammatory Applications:
4-Hydroxy-7-Methylquinoline-3-carboxylic acid is being studied for its potential use in anti-inflammatory drugs. Its unique structure and functional properties may contribute to the development of effective treatments for various inflammatory conditions.
Used in Antioxidant Applications:
4-Hydroxy-7-Methylquinoline-3-carboxylic acid has been shown to exhibit antioxidant activities, making it a valuable compound for various industrial and pharmaceutical applications. Its potential use in this area could contribute to the development of products with antioxidant properties, promoting health and wellness.

Upstream product

• 108-44-1 1-amino-3-methylbenzene 
• 19056-83-8 diethyl 2-{[(3-methylphenyl)amino]methylene}propane-1,3-dioate 
• 41460-18-8 ethyl 4-hydroxy-7-methylquinoline-3-carboxylate 

Downstream Products

• 63136-61-8 4-chloro-7-methyl-quinoline 
• 124519-38-6 7-Methyl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid [4-(4-benzhydryl-piperazin-1-yl)-butyl]-amide 
• 82121-08-2 4-hydroxy-7-methylquinoline 

Relevant academic research and scientific papers

Nitrogen-containing heterocyclic compound as well as preparation method, pharmaceutical composition and application thereof

The invention provides a nitrogen-containing heterocyclic compound as well as a preparation method, a pharmaceutical composition and application thereof, and particularly provides a compound as shownin a formula I which is described in the specification,

Structure-activity relationships for ferriprotoporphyrin IX association and β-hematin inhibition by 4-aminoquinolines using experimental and ab initio methods

In order to probe structure-activity relationships of association with ferriprotoporphyrin IX (log K) and inhibition of β-hematin formation, a series of 4-aminoquinolines with varying substituents at the 7-position (X) have been synthesized. These have been further elaborated by introduction of two different R groups on the 4-amino nitrogen atom in the form of methyl (R = Me) and ethylamine (R = EtNH2) side chains. Data for a previously investigated series containing an N,N-diethyl-ethylamine side chain were also compared with the findings of this study. Experimentally, log K values for the simple 4-aminoquinoline series (R = H) were found to correlate with the hydrophobicity constant (π) of the group X. The log K values for the series with R = Me and EtNH2 were found to correlate with those of the series with R = H. The log of the 50% β-hematin inhibitory activity (log BHIA50) was found to correlate with log K and either meta (σm) or para (σp) Hammett constants for the series with R = Me and EtNH2, but not the simple series with R = H. To further improve predictability, correlations with ab initio electrostatic parameters, namely Mulliken and CHelpG charges were investigated. The best correlations were found with CHelpG charges which indicated that log K values can be predicted from the charges on atom H-8 and the group X in the quinolinium species computed in vacuum, while log BHIA50 values can be predicted from the CHelpG charges on C-7, C-8 and N-1 for the neutral species in vacuum. These correlations indicate that association and inhibition of β-hematin formation are separately determined. They also suggest that electron withdrawing groups at the 7-position, but not necessarily hydrophobic groups are required for hemozoin inhibition. The upshot is that the correlations imply that considerably more hydrophilic hemozoin inhibitors are feasible.

Design, synthesis, and biological evaluation of novel quinoline derivatives as HIV-1 Tat-TAR interaction inhibitors

Thirty-two quinoline derivatives were designed and synthesized as HIV-1 Tat-TAR interaction inhibitors. All the compounds showed high antiviral activities in inhibiting the formation of SIV-induced syncytium in CEM174 cells. Nine of them with low cytotoxicities were evaluated by Tat dependent HIV-1 LTR-driven CAT gene expression colorimetric enzyme assay in human 293T cells, indicating effective inhibitory activities of blocking the Tat-TAR interaction. Molecular modeling experiments indicated that these compounds may inhibit Tat-TAR interaction by binding to Tat protein instead of TAR RNA.

Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof

Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.

Synthesis of 1,4-Dihydro-4-oxo-quinoline-3-carboxylic Acid Derivatives as Inhibitors of Rat Lens Aldose Reductase

The title compounds were prepared according to Scheme 2 and tested as inhibitors of the aldose reductase of rat lens.